A lot less attention has been paid to what happens after a vaccine is approved by the regulators.
As recognised by a US scientific committee, governments need to start planning how they will distribute a vaccine efficiently and fairly, because, when a vaccine is approved, most countries won’t have enough doses to vaccinate everyone.
Read the full article on The Conversation website, written by Laurence Roope and Philip Clarke, Nuffield Department of Population Health
Oxford is a subscribing member of The Conversation. Find out how you can write for The Conversation.